John M Vierling
Overview
Explore the profile of John M Vierling including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
134
Citations
4525
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Camara Dit Pinto S, Cherkaoui J, Ghosh D, Cazaubon V, Benzeroual K, Levine S, et al.
NPJ Digit Med
. 2024 Nov;
7(1):340.
PMID: 39604584
Addressing drug-induced liver injury is crucial in drug development, often causing Phase III trial failures and market withdrawals. Traditional animal models fail to predict human liver toxicity accurately. Virtual twins...
2.
Tanaka A, Ma X, Takahashi A, Vierling J
Lancet
. 2024 Aug;
404(10457):1053-1066.
PMID: 39216494
Primary biliary cholangitis is a chronic, autoimmune, cholestatic disease that mainly affects women aged 40-70 years. Recent epidemiological studies have shown an increasing incidence worldwide despite geographical heterogeneity and a...
3.
Sanchez J, Fontillas A, Kwan S, Sanchez C, Calderone T, Lee J, et al.
JHEP Rep
. 2024 Aug;
6(8):101119.
PMID: 39139459
Background & Aims: The effectiveness of surveillance for hepatocellular carcinoma (HCC) in patients with cirrhosis is limited, due to inadequate risk stratification and suboptimal performance of current screening modalities. Methods:...
4.
Clark V, Strange C, Strnad P, Sanchez A, Kwo P, Pereira V, et al.
Gastroenterology
. 2024 Jul;
167(5):1008-1018.e5.
PMID: 38964420
Background & Aims: Homozygous ZZ alpha-1 antitrypsin (AAT) deficiency produces mutant AAT (Z-AAT) proteins in hepatocytes, leading to progressive liver fibrosis. We evaluated the safety and efficacy of an investigational...
5.
Hirschfield G, Bowlus C, Mayo M, Kremer A, Vierling J, Kowdley K, et al.
N Engl J Med
. 2024 Feb;
390(9):783-794.
PMID: 38381664
Background: Effective treatments for patients with primary biliary cholangitis are limited. Seladelpar, a peroxisome proliferator-activated receptor delta agonist, has potential benefits. Methods: In this phase 3, 12-month, double-blind, placebo-controlled trial,...
6.
Kochhar S, Assis D, Mack C, Izurieta H, Muratori L, Munoz A, et al.
Vaccine
. 2024 Feb;
42(7):1812-1825.
PMID: 38368225
This report introduces a Brighton Collaboration (BC) case definition for autoimmune hepatitis (AIH), which has been classified as a priority adverse event of special interest (AESI), as there were possible...
7.
Cohen E, Regev A, Garg A, Di Bisceglie A, Lewis J, Vierling J, et al.
Drug Saf
. 2024 Feb;
47(4):321-332.
PMID: 38353882
Hepatitis B virus reactivation (HBVr) during and after immunosuppressive/immunomodulatory (IS/IM) therapy is associated with significant morbidity and mortality, including hepatic decompensation and acute liver failure. The risk of HBVr with...
8.
Trivedi P, Hirschfield G, Adams D, Vierling J
Gastroenterology
. 2024 Feb;
166(6):995-1019.
PMID: 38342195
Autoimmune liver diseases include primary biliary cholangitis, primary sclerosing cholangitis, and autoimmune hepatitis, a family of chronic immune-mediated disorders that target hepatocytes and cholangiocytes. Treatments remain nonspecific, variably effective, and...
9.
Mayo M, Vierling J, Bowlus C
Aliment Pharmacol Ther
. 2023 Dec;
59(2):282.
PMID: 38153281
No abstract available.
10.
Kowdley K, Bowlus C, Levy C, Akarca U, Alvares-da-Silva M, Andreone P, et al.
N Engl J Med
. 2023 Nov;
390(9):795-805.
PMID: 37962077
Background: Primary biliary cholangitis is a rare, chronic cholestatic liver disease characterized by the destruction of interlobular bile ducts, leading to cholestasis and liver fibrosis. Whether elafibranor, an oral, dual...